AAV-2: how can the capsid be modified to improve the viral vector in gene therapy?

Author： Kreppel Florian  

Publisher： Future Medicine

ISSN： 1746-0794

Source： Future Virology, Vol.5, Iss.2, 2010-03, pp. : 133-135

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Viral Vector-Mediated Gene Therapy for Hemophilia

By  

Current Gene Therapy, Vol. 1, Iss. 3, 2001-09 ,pp. : 301-315

Bentham Science Publishers

Access to resources Recommend Favorite

Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy

By  

Current Gene Therapy, Vol. 2, Iss. 3, 2002-09 ,pp. : 273-293

Bentham Science Publishers

Access to resources Recommend Favorite

From Virus Evolution to Vector Revolution: Use of Naturally Occurring Serotypes of Adeno-associated Virus (AAV) as Novel Vectors for Human Gene Therapy

By  

Current Gene Therapy, Vol. 3, Iss. 4, 2003-01 ,pp. : 281-304

Bentham Science Publishers

Access to resources Recommend Favorite

Why Do We Need New Gene Therapy Viral Vectors? Characteristics, Limitations and Future Perspectives of Viral Vector Transduction

By  

Current Gene Therapy, Vol. 4, Iss. 4, 2004-12 ,pp. : 357-372

Bentham Science Publishers

Access to resources Recommend Favorite

The Problem with Cationic Liposome / Micelle-Based Non-Viral Vector Systems for Gene Therapy

By  

Current Medicinal Chemistry, Vol. 10, Iss. 14, 2003-07 ,pp. : 1195-1211

Bentham Science Publishers

Access to resources Recommend Favorite